Brooks Laboratories accepts resignation of company secretary
- Brooks Laboratories accepts resignation of Company Secretary Ms. Krutika Rane
- Effective date for cessation of duties is October 9, 2026
- Reason cited is pursuit of alternate career opportunity outside organization
- Disclosure made under Regulation 30 of SEBI Listing Regulations on September 16, 2026

*this image is generated using AI for illustrative purposes only.
Brooks Laboratories Limited has accepted the resignation of Ms. Krutika Rane as Company Secretary and Compliance Officer. Her departure is effective from the close of business on October 9, 2026.
Ms. Rane cited an alternate career opportunity outside the organization as the reason for her exit. The company disclosed this development in a filing dated September 16, 2026.
Regulatory Compliance
The intimation was issued in accordance with Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Brooks Laboratories informed both the BSE Limited and the National Stock Exchange of India Ltd regarding the change in Key Managerial Personnel.
Resignation Details
Ms. Rane submitted her resignation letter to the Board of Directors on September 16, 2026. In her letter, she thanked the board for their support during her tenure and requested the necessary filings with the Registrar of Companies and stock exchanges to effectuate the resignation.
| Particulars | Details |
|---|---|
| Name | Ms. Krutika Rane |
| Designation | Company Secretary and Compliance Officer |
| Reason | Alternate career opportunity |
| Effective Date | October 9, 2026 |
Bhushan Singh Rana, Whole-Time Director, signed the disclosure on behalf of the company.
Historical Stock Returns for Brooks Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.28% | -3.60% | -2.23% | +4.90% | -61.24% | -59.01% |
Has Brooks Laboratories identified a successor for the Company Secretary role, and what is the expected timeline for appointment?
Could this leadership change in compliance signal any underlying internal governance issues or upcoming strategic shifts at the company?
How might the transition period affect Brooks Laboratories' ability to meet upcoming regulatory filing deadlines with SEBI?


































